Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

816.40 -10.01 (-1.21%)
Streaming Delayed Price Updated: 11:41 AM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets
ICER finds semaglutide and tirzepatide cost-effective for obesity but flags major affordability concerns and limited patient access at current prices. 
Via Benzinga
The Smartest Vanguard ETF to Buy With $1,000 Right Now
A fund like the Vanguard Dividend Appreciation ETF can help hedge against a potential market pullback. 
Via The Motley Fool
Topics ETFs
Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'
Novo Nordisk (NYSE: NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant... 
Via Benzinga
Eli Lilly, Novo Nordisk’s Weight-Loss Drugs Deemed Cost-Effective By Pricing Watchdog: BofA Deems Decision A ‘Win’
Via Stocktwits
Defiance Has A New ETF For High-Stakes Pharma Traders
Defiance's LLYZ ETF offers 2X inverse daily exposure to Eli Lilly, giving traders a high-risk, short-term way to bet on stock pullbacks without shorting. 
Via Benzinga
Topics ETFs
Eli Lilly Meshes AI With Drug Research, Touts $1B Worth Of Research Data
Eli Lilly's new TuneLab platform gives biotech firms AI-powered drug discovery tools using $1 billion of proprietary research. 
Via Benzinga
Topics Artificial Intelligence
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies
The platform will provide biotech companies access to drug discovery models trained on years of Lilly's research data, the company stated. 
Via Stocktwits
Topics Artificial Intelligence
2 Growth Stocks with Explosive Upside and 1 We Brush Off
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Topics Credit Cards
1 Reason Every Investor Should Know About Novo Nordisk (NVO)
The company could be on the verge of turning the tide in the battle over weight loss drugs. 
Via The Motley Fool
Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients
Jaypirca outperformed chemoimmunotherapy in progression-free survival for chronic lymphocytic leukemia patients in a Phase 3 trial, with positive trends in overall survival. 
Via Benzinga
2024 R&D Spending and Intensity Benchmarks
Via PRLog
Topics Supply Chain
Ozempic Is The New Botox And Big Pharma Is Printing Billions
Ozempic and Zepbound have helped Novo Nordisk and Eli Lilly achieve a combined market cap topping $900 billion. 
Via Benzinga
Looking At Eli Lilly's Recent Unusual Options Activity
 
Via Benzinga
Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (NYSE:LLY) and the best and worst... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List
FDA introduces a green list to block unsafe GLP-1 drug imports, while WHO updates its essential medicines list to include diabetes and cancer treatments. 
Via Benzinga
Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.
The market may have been too quick to dismiss this biotech's pipeline prospects after a recent trial result. 
Via The Motley Fool
The Best Growth ETF to Invest $2,000 in Right Now
This ETF has shown long-term market-beating ability. 
Via The Motley Fool
Topics ETFs
3 Stocks to Buy and Hold Forever
These stocks are built for the long run. 
Via The Motley Fool
Topics Intellectual Property
Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data
Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk. 
Via Benzinga
Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day?
The company's innovative engine continues to function well. 
Via The Motley Fool
Topics World Trade
2 S&P 500 Dividend Stocks That Could Climb More Than 20% According to Wall Street Analysts
Consensus price targets set by experts who follow these businesses are way above their recent prices. 
Via The Motley Fool
Topics Stocks
Down 34%, Should You Buy the Dip on Viking Therapeutics?
Viking aims to enter the billion-dollar weight loss drug market. 
Via The Motley Fool
FDA Breakthrough Status Awarded To Lilly-Merck Combo Drug For Advanced Non-Small Cell Lung Cancer
Eli Lilly's olomorasib with Merck's Keytruda receives FDA Breakthrough Therapy status for KRAS G12c lung cancer, supported by trial results. 
Via Benzinga
ETF Traders Are Quietly Positioning For Market Turbulence: Direxion
Direxion MD Edward Egilinsky says traders are locking profits, hedging market highs, and using Palantir inverse ETFs for tactical moves. 
Via Benzinga
Topics ETFs
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years
Both companies have made significant progress in recent years. 
Via The Motley Fool
The 6 Best Stocks to Buy Right Now in September (2025)!
There is something for everyone in this list of excellent stocks to buy. 
Via The Motley Fool
Where Will Eli Lilly Be in 3 Years?
The weight-loss drug opportunity could approach $100 billion by the end of the decade. 
Via The Motley Fool
Topics Intellectual Property
The Problem With Weight Loss Stocks
There are new ways to tackle weight loss, but the stocks leading the way are lagging. 
Via The Motley Fool
Topics Economy
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.